中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

乙型肝炎肝硬化患者促凝和抗凝血因子变化分析

邓永东 彭雪彬 姚立琼 李海 谭榜云 马超群

引用本文:
Citation:

乙型肝炎肝硬化患者促凝和抗凝血因子变化分析

DOI: 10.3969/j.issn.1001-5256.2019.02.020
基金项目: 

甘肃省科技计划资目——甘肃省自然科学基金(17JR5RA270); 

详细信息
  • 中图分类号: R512.62;R575.2

Changes in procoagulant and anticoagulant factors in patients with hepatitis B cirrhosis

Research funding: 

 

  • 摘要: 目的了解乙型肝炎肝硬化患者的促凝、抗凝血因子以及临床常规凝血指标的变化,明确其临床意义。方法选取2017年1月-2018年10月于兰州大学第一医院感染科门诊及住院的乙型肝炎肝硬化患者105例,根据Child-Pugh分级分为3组:A级组(n=42)、B级组(n=39)、C级组(n=24),对所有患者检测常用临床凝血指标如凝血酶原时间(PT)、活化部分凝血酶原时间(APTT),凝血因子(Ⅱ、Ⅴ、Ⅶ、Ⅷ、Ⅺ),抗凝血因子抗凝血酶(AT)、蛋白C(PC)、游离蛋白S(FPS)。计量资料多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验,相关性分析采用Spearman相关分析法。结果不同Child-Pugh分级的乙型肝炎肝硬化患者PT、APTT差异均有统计学意义(F值分别为55. 11、12. 09,P值均<0. 001),C级组均显著高于B级和A级组,B级组均显著高于A级组(P值均<0. 05)。凝血因子Ⅱ、Ⅴ、Ⅶ、Ⅺ活性在不同Child-Pugh分级的乙型肝炎肝硬化患者中差异均有统计学意义(F值分别为32. 52、14. 77、38. 88、9. 24,P值均<...

     

  • [1]TSOCHATZIS EA, SENZOLO M, GERMANI G, et al.Systematic review:Portal veinthrombosis in cirrhosis[J].Aliment Pharmacol Ther, 2010, 31 (3) :366-374.
    [2]LISMAN T, PORTE RJ.Rebalanced hemostasis in patients with liver disease:Evidence and clinical consequences[J].Blood, 2010, 116 (6) :878-885.
    [3]TRIPODI A, ANSTEE QM, SOGAARD KK, et al.Hypercoagulability in cirrhosis:Causes and consequences[J].J Thromb Haemost, 2011, 9 (9) :1713-1723.
    [4]AMBROSINO P, TARANTINO L, DI MINNO G, et al.The risk of venous thromboembolism in patients with cirrhosis.A systematic review and meta-analysis[J].Thromb Haemost, 2017, 117 (1) :139-148.
    [5]CHEN DF, XIONG J.Advances in mechanisms and treatment of portal vein thrombosis in patients with liver cirrhosis[J].JClin Hepatol, 2017, 33 (3) :451-453. (in Chinese) 陈东风, 熊吉.肝硬化门静脉血栓形成的机制与治疗进展[J].临床肝胆病杂志, 2017, 33 (3) :451-453.
    [6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
    [7]FERRO D, ANGELICO F, CALDWELL SH, et al.Bleeding and thrombosis in cirrhotic patients:What really matters?[J].Dig Liver Dis, 2012, 44 (4) :275-279.
    [8]CARNEVALE R, RAPARELLI V, NOCELLA C, et al.Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells.Implications for hypercoagulability in cirrhosis[J].JHepatol, 2017, 67 (5) :950-956.
    [9]SHOVLIN CL, ANGUS G, MANNING RA, et al.Endothelial cell processing and alternatively spliced transcripts of factor VIII:Potential implications for coagulation cascades and pulmonary hypertension[J].PLo S One, 2010, 5 (5) :e9154.
    [10]IKURA Y, OSUGA T.Changing common sense:Anti-platelet/coagulation therapy against cirrhosis[J].World J Hepatol, 2015, 8 (13) :1730-1734.
    [11]TRIPODI A.Hemostasis abnormalities in chronic liver failure[M]//GINS P, KAMATH P, ARROYO V.Chronic liver failure.Clinical Gastroenterology.Humana Press, 2011:289-303.
    [12]BACCOUCHE H, LABIDI A, FEKIH M, et al.Haemostatic balance in cirrhosis[J].Blood Coagul Fibrinolysis, 2017, 28 (2) :139-144.
  • 加载中
计量
  • 文章访问数:  1719
  • HTML全文浏览量:  65
  • PDF下载量:  289
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-09-20
  • 出版日期:  2019-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回